Log in
Enquire now
‌

US Patent 11219674 Therapeutic cancer vaccine

Patent 11219674 was granted and assigned to Cadila Pharmaceuticals on January, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Cadila Pharmaceuticals
Cadila Pharmaceuticals
Current Assignee
Cadila Pharmaceuticals
Cadila Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11219674
Patent Inventor Names
Nirav Manojkumar Desai0
Bakulesh Mafatlal Khamar0
Chandreshwar Prasad Shukla0
Indravadan Ambalal Modi0
Avani Devenbhai Darji0
Date of Patent
January 11, 2022
Patent Application Number
16404902
Date Filed
May 7, 2019
Patent Primary Examiner
‌
Stephen L. Rawlings
Patent abstract

The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ. The invention also provides method of preparing the same.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11219674 Therapeutic cancer vaccine

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.